Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 30 | 2023 | 3615 | 1.300 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 31 | 2022 | 11742 | 0.870 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2021 | 686 | 0.860 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 1 | 2021 | 37 | 0.780 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2022 | 1551 | 0.750 |
Why?
|
Pyrimidines | 5 | 2020 | 3028 | 0.460 |
Why?
|
Thiazoles | 2 | 2011 | 1517 | 0.440 |
Why?
|
Cytarabine | 12 | 2019 | 698 | 0.420 |
Why?
|
fms-Like Tyrosine Kinase 3 | 5 | 2017 | 495 | 0.410 |
Why?
|
Leukemia, Myeloid | 7 | 2019 | 694 | 0.410 |
Why?
|
Remission Induction | 16 | 2022 | 2397 | 0.390 |
Why?
|
Glutarates | 3 | 2018 | 243 | 0.330 |
Why?
|
Head and Neck Neoplasms | 9 | 2005 | 2894 | 0.300 |
Why?
|
Aminoacridines | 5 | 1984 | 9 | 0.290 |
Why?
|
Paranasal Sinus Neoplasms | 2 | 2002 | 242 | 0.290 |
Why?
|
Carcinoma, Squamous Cell | 9 | 2005 | 4024 | 0.270 |
Why?
|
Azepines | 2 | 2019 | 329 | 0.270 |
Why?
|
Maximum Tolerated Dose | 8 | 2019 | 883 | 0.260 |
Why?
|
Translocation, Genetic | 4 | 2014 | 1393 | 0.240 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2019 | 1640 | 0.240 |
Why?
|
Asparaginase | 2 | 2017 | 240 | 0.240 |
Why?
|
Jehovah's Witnesses | 1 | 2004 | 13 | 0.230 |
Why?
|
Mitoxantrone | 6 | 2019 | 148 | 0.230 |
Why?
|
Vincristine | 5 | 2022 | 1036 | 0.230 |
Why?
|
Freedom | 1 | 2004 | 69 | 0.230 |
Why?
|
Isocitrate Dehydrogenase | 4 | 2023 | 938 | 0.230 |
Why?
|
Myelodysplastic Syndromes | 3 | 2019 | 1394 | 0.210 |
Why?
|
Proto-Oncogenes | 1 | 2004 | 321 | 0.210 |
Why?
|
Antineoplastic Agents | 12 | 2019 | 13642 | 0.210 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2004 | 410 | 0.210 |
Why?
|
Nose Neoplasms | 2 | 2002 | 249 | 0.210 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2004 | 418 | 0.200 |
Why?
|
Leukemia, Eosinophilic, Acute | 1 | 2021 | 5 | 0.200 |
Why?
|
Treatment Refusal | 2 | 2004 | 429 | 0.190 |
Why?
|
Steel | 1 | 2021 | 27 | 0.190 |
Why?
|
Oncogene Proteins, Fusion | 4 | 2022 | 1609 | 0.190 |
Why?
|
Oral Ulcer | 1 | 2021 | 96 | 0.180 |
Why?
|
Idarubicin | 4 | 2019 | 59 | 0.180 |
Why?
|
Boron Compounds | 1 | 2022 | 182 | 0.180 |
Why?
|
Esthesioneuroblastoma, Olfactory | 2 | 1999 | 58 | 0.170 |
Why?
|
Blood Transfusion | 2 | 2004 | 1301 | 0.170 |
Why?
|
Blast Crisis | 1 | 2020 | 102 | 0.170 |
Why?
|
Leukemia | 3 | 2004 | 1522 | 0.170 |
Why?
|
Philadelphia Chromosome | 1 | 2020 | 117 | 0.170 |
Why?
|
Aged | 53 | 2022 | 169310 | 0.170 |
Why?
|
Fluorouracil | 5 | 2000 | 1642 | 0.160 |
Why?
|
Cisplatin | 7 | 2002 | 1652 | 0.160 |
Why?
|
Hematologic Neoplasms | 1 | 2011 | 1896 | 0.160 |
Why?
|
Mutation | 10 | 2019 | 30053 | 0.160 |
Why?
|
Uridine | 1 | 2019 | 141 | 0.160 |
Why?
|
Long QT Syndrome | 1 | 2023 | 467 | 0.160 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2019 | 5305 | 0.160 |
Why?
|
Etoposide | 5 | 2019 | 634 | 0.160 |
Why?
|
Glycine | 1 | 2022 | 663 | 0.150 |
Why?
|
Alveolar Ridge Augmentation | 1 | 2020 | 208 | 0.150 |
Why?
|
Alveolar Bone Loss | 1 | 2020 | 390 | 0.140 |
Why?
|
Neoplasm Invasiveness | 1 | 2005 | 3597 | 0.140 |
Why?
|
Antigens, CD19 | 1 | 2020 | 424 | 0.140 |
Why?
|
Middle Aged | 60 | 2020 | 220921 | 0.140 |
Why?
|
Humans | 89 | 2023 | 761596 | 0.130 |
Why?
|
Male | 62 | 2022 | 360846 | 0.130 |
Why?
|
Neuroendocrine Tumors | 1 | 2002 | 641 | 0.130 |
Why?
|
Recurrence | 7 | 2023 | 8466 | 0.120 |
Why?
|
SEER Program | 3 | 2017 | 1450 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2013 | 9280 | 0.120 |
Why?
|
Antifungal Agents | 1 | 2020 | 753 | 0.120 |
Why?
|
Bone Marrow | 5 | 2021 | 2911 | 0.120 |
Why?
|
Bleomycin | 3 | 1992 | 494 | 0.120 |
Why?
|
Protein Kinase Inhibitors | 3 | 2017 | 5672 | 0.120 |
Why?
|
Glutamine | 1 | 2017 | 577 | 0.120 |
Why?
|
Anilides | 1 | 2017 | 411 | 0.120 |
Why?
|
Core Binding Factors | 1 | 2014 | 29 | 0.120 |
Why?
|
Female | 63 | 2021 | 392705 | 0.120 |
Why?
|
Sarcoma, Myeloid | 1 | 2014 | 51 | 0.120 |
Why?
|
Myeloproliferative Disorders | 2 | 2011 | 613 | 0.110 |
Why?
|
Aziridines | 3 | 1998 | 21 | 0.110 |
Why?
|
Drug Administration Schedule | 7 | 2019 | 4853 | 0.110 |
Why?
|
Adult | 45 | 2020 | 221210 | 0.110 |
Why?
|
Physician-Patient Relations | 2 | 2018 | 3251 | 0.100 |
Why?
|
Survival Analysis | 9 | 2017 | 10090 | 0.100 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 1997 | 339 | 0.100 |
Why?
|
Benzoquinones | 3 | 1998 | 198 | 0.100 |
Why?
|
Magnetic Resonance Imaging | 7 | 2021 | 36426 | 0.100 |
Why?
|
Surgery, Computer-Assisted | 1 | 2020 | 1007 | 0.100 |
Why?
|
Treatment Outcome | 15 | 2022 | 64685 | 0.100 |
Why?
|
Immunoconjugates | 1 | 2019 | 953 | 0.100 |
Why?
|
Dental Implants | 1 | 2020 | 795 | 0.100 |
Why?
|
Combined Modality Therapy | 7 | 2016 | 8527 | 0.100 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2023 | 5672 | 0.100 |
Why?
|
Survival Rate | 8 | 2018 | 12723 | 0.100 |
Why?
|
Prognosis | 12 | 2019 | 29629 | 0.100 |
Why?
|
Boronic Acids | 3 | 2013 | 915 | 0.090 |
Why?
|
Leukocytosis | 1 | 2012 | 251 | 0.090 |
Why?
|
Aged, 80 and over | 18 | 2020 | 58984 | 0.090 |
Why?
|
Affect | 1 | 2019 | 1486 | 0.090 |
Why?
|
Chromosomes, Human, Pair 21 | 2 | 2014 | 228 | 0.090 |
Why?
|
Amsacrine | 6 | 1986 | 19 | 0.090 |
Why?
|
Immunotherapy, Adoptive | 1 | 2020 | 1469 | 0.090 |
Why?
|
DNA-Binding Proteins | 2 | 2005 | 9610 | 0.090 |
Why?
|
Disease-Free Survival | 8 | 2019 | 6815 | 0.090 |
Why?
|
Needs Assessment | 1 | 2016 | 1139 | 0.090 |
Why?
|
In Situ Hybridization, Fluorescence | 4 | 2022 | 2510 | 0.090 |
Why?
|
Salivary Gland Neoplasms | 2 | 2004 | 304 | 0.080 |
Why?
|
Pyrazines | 3 | 2013 | 1202 | 0.080 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2021 | 2791 | 0.080 |
Why?
|
Cell Death | 1 | 2015 | 1679 | 0.080 |
Why?
|
Methotrexate | 2 | 2014 | 1719 | 0.080 |
Why?
|
Salvage Therapy | 5 | 2017 | 1263 | 0.080 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2010 | 251 | 0.080 |
Why?
|
Communicable Diseases | 1 | 2017 | 875 | 0.080 |
Why?
|
Models, Theoretical | 1 | 2021 | 3575 | 0.080 |
Why?
|
Interferon-alpha | 1 | 1993 | 921 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1367 | 0.080 |
Why?
|
Enzyme Inhibitors | 2 | 2017 | 3713 | 0.080 |
Why?
|
Hospitalization | 2 | 2019 | 10721 | 0.070 |
Why?
|
Transcription Factors | 2 | 2005 | 12130 | 0.070 |
Why?
|
Radiography, Abdominal | 1 | 2011 | 534 | 0.070 |
Why?
|
Quinazolines | 1 | 2013 | 1371 | 0.070 |
Why?
|
Budd-Chiari Syndrome | 1 | 2006 | 24 | 0.070 |
Why?
|
Drug Evaluation | 6 | 1986 | 641 | 0.070 |
Why?
|
Nausea | 3 | 1999 | 679 | 0.070 |
Why?
|
Interleukin-2 | 1 | 1993 | 1889 | 0.070 |
Why?
|
Central Nervous System Neoplasms | 1 | 2014 | 916 | 0.070 |
Why?
|
Amifostine | 1 | 2005 | 40 | 0.060 |
Why?
|
Vascular Neoplasms | 1 | 2007 | 166 | 0.060 |
Why?
|
Intensive Care Units | 1 | 2019 | 3744 | 0.060 |
Why?
|
Soft Tissue Neoplasms | 1 | 2014 | 1159 | 0.060 |
Why?
|
Insurance Coverage | 1 | 2017 | 1940 | 0.060 |
Why?
|
Pyridines | 1 | 2017 | 2875 | 0.060 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2013 | 646 | 0.060 |
Why?
|
Hospital Mortality | 1 | 2019 | 5293 | 0.060 |
Why?
|
Radiotherapy Dosage | 2 | 2005 | 2898 | 0.060 |
Why?
|
Acute Disease | 7 | 2019 | 7237 | 0.060 |
Why?
|
Neurodegenerative Diseases | 1 | 2014 | 1088 | 0.060 |
Why?
|
Insurance, Health | 1 | 2017 | 2499 | 0.060 |
Why?
|
Purine Nucleosides | 1 | 2003 | 30 | 0.060 |
Why?
|
Alkyl and Aryl Transferases | 1 | 2004 | 86 | 0.060 |
Why?
|
Tissue Distribution | 1 | 2008 | 2264 | 0.060 |
Why?
|
Minors | 1 | 2004 | 58 | 0.060 |
Why?
|
Chromosomes, Human, X | 1 | 2005 | 321 | 0.060 |
Why?
|
Terminal Care | 1 | 2015 | 1761 | 0.050 |
Why?
|
Follow-Up Studies | 7 | 2019 | 39106 | 0.050 |
Why?
|
Stem Cell Transplantation | 1 | 2011 | 1600 | 0.050 |
Why?
|
Leukopenia | 3 | 1992 | 213 | 0.050 |
Why?
|
Young Adult | 9 | 2020 | 59260 | 0.050 |
Why?
|
Ultrafiltration | 1 | 1982 | 49 | 0.050 |
Why?
|
Neoplasm Staging | 4 | 2019 | 11120 | 0.050 |
Why?
|
Centrifugation | 1 | 1982 | 122 | 0.050 |
Why?
|
Leukapheresis | 1 | 1982 | 134 | 0.050 |
Why?
|
Identity Crisis | 1 | 2002 | 12 | 0.050 |
Why?
|
Paclitaxel | 3 | 2005 | 1732 | 0.050 |
Why?
|
Faith Healing | 1 | 2002 | 26 | 0.050 |
Why?
|
Cardiomyopathies | 1 | 2014 | 1964 | 0.050 |
Why?
|
Germany | 1 | 2004 | 875 | 0.050 |
Why?
|
Radiotherapy, High-Energy | 1 | 2002 | 228 | 0.050 |
Why?
|
Tandem Repeat Sequences | 2 | 2012 | 180 | 0.050 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 1 | 2004 | 305 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2015 | 3206 | 0.050 |
Why?
|
Isoflurophate | 1 | 1980 | 28 | 0.050 |
Why?
|
Nuclear Pore Complex Proteins | 1 | 2022 | 163 | 0.050 |
Why?
|
Lung Diseases, Interstitial | 1 | 2009 | 918 | 0.050 |
Why?
|
Lymphoma, B-Cell | 1 | 2007 | 940 | 0.040 |
Why?
|
Particle Accelerators | 1 | 2021 | 174 | 0.040 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2005 | 1784 | 0.040 |
Why?
|
Probability | 1 | 2005 | 2477 | 0.040 |
Why?
|
Taxoids | 2 | 2000 | 668 | 0.040 |
Why?
|
Acanthocytes | 1 | 1979 | 3 | 0.040 |
Why?
|
Blood | 1 | 1982 | 596 | 0.040 |
Why?
|
Adolescent | 10 | 2017 | 88326 | 0.040 |
Why?
|
Diffusion | 1 | 2021 | 814 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2008 | 3779 | 0.040 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2004 | 682 | 0.040 |
Why?
|
DNA Mutational Analysis | 2 | 2021 | 4111 | 0.040 |
Why?
|
Rotation | 1 | 2021 | 517 | 0.040 |
Why?
|
Chromosome Aberrations | 1 | 2005 | 1768 | 0.040 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 1 | 2002 | 324 | 0.040 |
Why?
|
Erythrocytes, Abnormal | 1 | 1979 | 121 | 0.040 |
Why?
|
RNA, Neoplasm | 1 | 2021 | 750 | 0.040 |
Why?
|
Dermatitis, Exfoliative | 1 | 1978 | 27 | 0.040 |
Why?
|
Computer-Aided Design | 1 | 2020 | 300 | 0.040 |
Why?
|
Pancytopenia | 1 | 1979 | 102 | 0.040 |
Why?
|
Thrombopoietin | 1 | 2000 | 226 | 0.040 |
Why?
|
Imidazoles | 1 | 2004 | 1180 | 0.040 |
Why?
|
Benzodiazepines | 1 | 2004 | 1132 | 0.040 |
Why?
|
Cytogenetic Analysis | 2 | 2011 | 270 | 0.040 |
Why?
|
Choroid Neoplasms | 1 | 1999 | 177 | 0.040 |
Why?
|
Administration, Oral | 3 | 2019 | 4021 | 0.040 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2007 | 1405 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 17904 | 0.040 |
Why?
|
Stomatitis | 1 | 1999 | 271 | 0.030 |
Why?
|
Anthracyclines | 1 | 2019 | 284 | 0.030 |
Why?
|
Eosinophilia | 1 | 2021 | 560 | 0.030 |
Why?
|
Protease Inhibitors | 1 | 1980 | 754 | 0.030 |
Why?
|
Nasal Cavity | 1 | 1999 | 304 | 0.030 |
Why?
|
Prospective Studies | 5 | 2018 | 54423 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2014 | 9420 | 0.030 |
Why?
|
Prednisone | 2 | 2014 | 1563 | 0.030 |
Why?
|
Receptor, erbB-2 | 2 | 2004 | 2557 | 0.030 |
Why?
|
DNA, Neoplasm | 1 | 2021 | 1745 | 0.030 |
Why?
|
Age Factors | 4 | 2017 | 18399 | 0.030 |
Why?
|
Dental Implantation, Endosseous | 1 | 2020 | 531 | 0.030 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2020 | 474 | 0.030 |
Why?
|
Trans-Activators | 1 | 2005 | 2856 | 0.030 |
Why?
|
Lipoproteins, LDL | 1 | 1979 | 642 | 0.030 |
Why?
|
Diagnosis, Differential | 4 | 2021 | 12973 | 0.030 |
Why?
|
Bone Transplantation | 1 | 2020 | 929 | 0.030 |
Why?
|
Databases, Factual | 3 | 2017 | 7968 | 0.030 |
Why?
|
Marital Status | 1 | 2017 | 426 | 0.030 |
Why?
|
Mandible | 1 | 2020 | 753 | 0.030 |
Why?
|
Body Mass Index | 1 | 2013 | 12953 | 0.030 |
Why?
|
Granulocytes | 1 | 1997 | 551 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2002 | 6312 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2020 | 909 | 0.030 |
Why?
|
Retrospective Studies | 7 | 2019 | 80647 | 0.030 |
Why?
|
Doxorubicin | 2 | 2014 | 2224 | 0.030 |
Why?
|
Drug Interactions | 1 | 2019 | 1416 | 0.030 |
Why?
|
Cold Temperature | 1 | 1978 | 785 | 0.030 |
Why?
|
Polyethylene Glycols | 1 | 2000 | 1189 | 0.030 |
Why?
|
Safety | 1 | 2019 | 1149 | 0.030 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 1997 | 629 | 0.030 |
Why?
|
Time Factors | 6 | 2016 | 39969 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2019 | 10766 | 0.030 |
Why?
|
Ovarian Neoplasms | 2 | 2015 | 4878 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1787 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 15502 | 0.030 |
Why?
|
Immunohistochemistry | 3 | 2016 | 11076 | 0.030 |
Why?
|
Granulocyte Precursor Cells | 1 | 2012 | 49 | 0.030 |
Why?
|
Daunorubicin | 1 | 2012 | 157 | 0.030 |
Why?
|
Brain | 1 | 2019 | 27121 | 0.030 |
Why?
|
Logistic Models | 2 | 2019 | 13255 | 0.030 |
Why?
|
Karyotyping | 1 | 2014 | 1171 | 0.030 |
Why?
|
Breast | 1 | 2021 | 1967 | 0.030 |
Why?
|
Carcinoma | 1 | 2004 | 2330 | 0.030 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2014 | 453 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2019 | 14608 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2017 | 637 | 0.020 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2012 | 317 | 0.020 |
Why?
|
Perception | 1 | 2018 | 1197 | 0.020 |
Why?
|
Signal Transduction | 1 | 2015 | 23447 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 1984 | 2297 | 0.020 |
Why?
|
Hot Temperature | 1 | 1978 | 1440 | 0.020 |
Why?
|
Peripheral Nervous System | 1 | 2012 | 151 | 0.020 |
Why?
|
Medically Uninsured | 1 | 2017 | 836 | 0.020 |
Why?
|
Biopsy | 2 | 2021 | 6766 | 0.020 |
Why?
|
Equipment Design | 1 | 2019 | 3511 | 0.020 |
Why?
|
Neoplasms | 2 | 2015 | 22173 | 0.020 |
Why?
|
Recombinant Proteins | 3 | 2000 | 6534 | 0.020 |
Why?
|
Risk Assessment | 2 | 2019 | 23996 | 0.020 |
Why?
|
Azacitidine | 1 | 2012 | 336 | 0.020 |
Why?
|
Inverted Repeat Sequences | 1 | 2010 | 60 | 0.020 |
Why?
|
Risk Factors | 4 | 2019 | 74213 | 0.020 |
Why?
|
Thrombocytopenia | 3 | 2000 | 1182 | 0.020 |
Why?
|
Incidence | 2 | 2020 | 21355 | 0.020 |
Why?
|
Liver | 1 | 2006 | 7528 | 0.020 |
Why?
|
Cell Line | 2 | 2015 | 15601 | 0.020 |
Why?
|
Ear, Middle | 1 | 1992 | 339 | 0.020 |
Why?
|
Bone and Bones | 1 | 2020 | 2568 | 0.020 |
Why?
|
Anorexia Nervosa | 1 | 1979 | 1361 | 0.020 |
Why?
|
Antibodies, Monoclonal | 2 | 2004 | 9177 | 0.020 |
Why?
|
Pain | 2 | 2021 | 5073 | 0.020 |
Why?
|
Comparative Genomic Hybridization | 1 | 2011 | 473 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2508 | 0.020 |
Why?
|
Educational Status | 1 | 2017 | 2522 | 0.020 |
Why?
|
Wound Healing | 1 | 2020 | 2805 | 0.020 |
Why?
|
Autoantibodies | 1 | 1978 | 2118 | 0.020 |
Why?
|
Aspirin | 1 | 1981 | 3133 | 0.020 |
Why?
|
Leukocytes | 2 | 1974 | 2026 | 0.020 |
Why?
|
Radiography | 3 | 2007 | 6965 | 0.020 |
Why?
|
Pyrazoles | 1 | 2020 | 2009 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3639 | 0.020 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2012 | 651 | 0.020 |
Why?
|
Erythrocytes | 1 | 1978 | 2413 | 0.020 |
Why?
|
Lung | 1 | 2007 | 10002 | 0.020 |
Why?
|
Leucovorin | 2 | 2001 | 643 | 0.020 |
Why?
|
Palliative Care | 3 | 2016 | 3598 | 0.020 |
Why?
|
Decision Making | 2 | 2018 | 3929 | 0.020 |
Why?
|
Drug Synergism | 1 | 2012 | 1757 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 1984 | 4317 | 0.020 |
Why?
|
Income | 1 | 2017 | 1877 | 0.020 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2012 | 1435 | 0.020 |
Why?
|
Social Class | 1 | 2017 | 2004 | 0.020 |
Why?
|
Fatal Outcome | 2 | 2005 | 1835 | 0.020 |
Why?
|
Thalidomide | 1 | 2013 | 885 | 0.020 |
Why?
|
Neutrophils | 1 | 1980 | 3767 | 0.020 |
Why?
|
Lung Neoplasms | 3 | 2007 | 13381 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2017 | 2048 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2011 | 20568 | 0.020 |
Why?
|
Mice, Nude | 1 | 2014 | 3614 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2016 | 4807 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2643 | 0.020 |
Why?
|
Fibrinogen | 1 | 2010 | 888 | 0.020 |
Why?
|
Kidney Neoplasms | 1 | 1983 | 4251 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 1 | 2020 | 4062 | 0.020 |
Why?
|
Antibodies | 1 | 1974 | 2418 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9327 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2011 | 2115 | 0.020 |
Why?
|
Immunotherapy | 1 | 2022 | 4652 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 1983 | 6345 | 0.020 |
Why?
|
Platelet Count | 2 | 2000 | 781 | 0.020 |
Why?
|
Factor V | 1 | 2006 | 167 | 0.020 |
Why?
|
Melanoma | 1 | 1984 | 5709 | 0.020 |
Why?
|
Poverty | 1 | 2017 | 2697 | 0.020 |
Why?
|
Cohort Studies | 1 | 2008 | 41495 | 0.020 |
Why?
|
Spine | 1 | 1992 | 1118 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2014 | 6214 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2009 | 1869 | 0.010 |
Why?
|
Liver Function Tests | 1 | 2006 | 523 | 0.010 |
Why?
|
Farnesyltranstransferase | 1 | 2004 | 71 | 0.010 |
Why?
|
Ascites | 1 | 2006 | 338 | 0.010 |
Why?
|
Duodenum | 1 | 2007 | 490 | 0.010 |
Why?
|
Anxiety | 1 | 2019 | 4573 | 0.010 |
Why?
|
Salmonella | 2 | 1974 | 125 | 0.010 |
Why?
|
Odds Ratio | 1 | 2016 | 9647 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2004 | 26202 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12059 | 0.010 |
Why?
|
Medicaid | 1 | 2017 | 2818 | 0.010 |
Why?
|
Carbon Radioisotopes | 2 | 1974 | 561 | 0.010 |
Why?
|
DNA Methylation | 1 | 2017 | 4399 | 0.010 |
Why?
|
Vena Cava, Inferior | 1 | 2006 | 458 | 0.010 |
Why?
|
Janus Kinase 2 | 1 | 2006 | 560 | 0.010 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2014 | 3612 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2017 | 12463 | 0.010 |
Why?
|
Salivary Glands | 1 | 2004 | 229 | 0.010 |
Why?
|
Neoplasm Metastasis | 2 | 2003 | 4915 | 0.010 |
Why?
|
Models, Chemical | 1 | 2004 | 611 | 0.010 |
Why?
|
Infant | 1 | 2004 | 36193 | 0.010 |
Why?
|
Christianity | 1 | 2002 | 50 | 0.010 |
Why?
|
Splenomegaly | 1 | 1982 | 189 | 0.010 |
Why?
|
Tegafur | 1 | 2001 | 39 | 0.010 |
Why?
|
Mitochondria | 1 | 2015 | 3624 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2007 | 2220 | 0.010 |
Why?
|
Renal Insufficiency | 1 | 2007 | 809 | 0.010 |
Why?
|
Bleeding Time | 1 | 1981 | 83 | 0.010 |
Why?
|
Child, Preschool | 1 | 2004 | 42232 | 0.010 |
Why?
|
Phenylmethylsulfonyl Fluoride | 1 | 1980 | 6 | 0.010 |
Why?
|
Ethylmaleimide | 1 | 1980 | 70 | 0.010 |
Why?
|
Phenanthrolines | 1 | 1980 | 50 | 0.010 |
Why?
|
Heart | 1 | 2014 | 4404 | 0.010 |
Why?
|
Egtazic Acid | 1 | 1980 | 167 | 0.010 |
Why?
|
Lymphatic Diseases | 1 | 1982 | 320 | 0.010 |
Why?
|
Edetic Acid | 1 | 1980 | 276 | 0.010 |
Why?
|
Carbon Dioxide | 2 | 1974 | 1147 | 0.010 |
Why?
|
Uracil | 1 | 2001 | 207 | 0.010 |
Why?
|
Fever | 1 | 2007 | 1618 | 0.010 |
Why?
|
Ultrasonography | 2 | 2006 | 5971 | 0.010 |
Why?
|
Area Under Curve | 1 | 2003 | 1638 | 0.010 |
Why?
|
Depression | 1 | 2019 | 8126 | 0.010 |
Why?
|
Blood Specimen Collection | 1 | 1980 | 238 | 0.010 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1986 | 1374 | 0.010 |
Why?
|
Antigens, CD | 1 | 2009 | 4001 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2003 | 2217 | 0.010 |
Why?
|
Hodgkin Disease | 1 | 1986 | 1378 | 0.010 |
Why?
|
Antigens, Bacterial | 2 | 1974 | 1154 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2007 | 2009 | 0.010 |
Why?
|
Pleural Neoplasms | 1 | 1983 | 609 | 0.010 |
Why?
|
Phagocytosis | 2 | 1974 | 1528 | 0.010 |
Why?
|
Risk | 1 | 2010 | 9610 | 0.010 |
Why?
|
Pilot Projects | 2 | 1997 | 8633 | 0.010 |
Why?
|
United States | 2 | 2017 | 72340 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4576 | 0.010 |
Why?
|
Religion | 1 | 2002 | 372 | 0.010 |
Why?
|
Registries | 1 | 2014 | 8225 | 0.010 |
Why?
|
Cerebellar Diseases | 1 | 2000 | 220 | 0.010 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 1980 | 1741 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 2000 | 1379 | 0.010 |
Why?
|
Microfilament Proteins | 1 | 1983 | 1134 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 2005 | 4615 | 0.010 |
Why?
|
Quality of Life | 1 | 2019 | 13367 | 0.010 |
Why?
|
Filgrastim | 1 | 1997 | 132 | 0.010 |
Why?
|
Drug Eruptions | 1 | 2000 | 335 | 0.010 |
Why?
|
Mouth Mucosa | 1 | 1999 | 432 | 0.010 |
Why?
|
Kidney | 1 | 1992 | 7048 | 0.010 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2006 | 2425 | 0.010 |
Why?
|
Random Allocation | 1 | 1981 | 2395 | 0.010 |
Why?
|
Ethics, Medical | 1 | 2002 | 783 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 5314 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 1984 | 2915 | 0.010 |
Why?
|
Child | 1 | 2004 | 80158 | 0.010 |
Why?
|
Actins | 1 | 1983 | 2050 | 0.010 |
Why?
|
Exanthema | 1 | 2000 | 503 | 0.010 |
Why?
|
Hip Prosthesis | 1 | 1981 | 921 | 0.010 |
Why?
|
Neutropenia | 1 | 2000 | 885 | 0.010 |
Why?
|
Disease Progression | 2 | 2003 | 13510 | 0.010 |
Why?
|
Latex Fixation Tests | 1 | 1974 | 29 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2013 | 5841 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 1982 | 21019 | 0.010 |
Why?
|
Immunologic Techniques | 1 | 1974 | 212 | 0.010 |
Why?
|
Fatigue | 1 | 2001 | 1552 | 0.010 |
Why?
|
Methods | 1 | 1974 | 1067 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2006 | 4514 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2013 | 6403 | 0.010 |
Why?
|
Leukocyte Count | 1 | 1997 | 1596 | 0.010 |
Why?
|
Serologic Tests | 1 | 1974 | 381 | 0.010 |
Why?
|
Glucose | 2 | 1974 | 4347 | 0.010 |
Why?
|
Hypertension | 1 | 1992 | 8540 | 0.010 |
Why?
|
Automation | 1 | 1974 | 586 | 0.010 |
Why?
|
Death, Sudden, Cardiac | 1 | 2000 | 1555 | 0.010 |
Why?
|
Syndrome | 1 | 1978 | 3267 | 0.010 |
Why?
|
Anemia | 1 | 2001 | 1509 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2003 | 3617 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2007 | 6484 | 0.010 |
Why?
|
Algorithms | 1 | 2011 | 14033 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2005 | 14665 | 0.010 |
Why?
|
Carrier Proteins | 1 | 1983 | 4937 | 0.010 |
Why?
|
Clinical Trials as Topic | 2 | 1986 | 8002 | 0.010 |
Why?
|
Cause of Death | 1 | 2000 | 3683 | 0.010 |
Why?
|
Dogs | 1 | 1974 | 3839 | 0.010 |
Why?
|
Mice | 1 | 2014 | 81539 | 0.000 |
Why?
|
Animals | 3 | 2014 | 168475 | 0.000 |
Why?
|
Double-Blind Method | 1 | 2000 | 12341 | 0.000 |
Why?
|
Skin Neoplasms | 1 | 1984 | 5821 | 0.000 |
Why?
|
Models, Structural | 1 | 1983 | 340 | 0.000 |
Why?
|
Microcomputers | 1 | 1983 | 141 | 0.000 |
Why?
|
Gelsolin | 1 | 1983 | 189 | 0.000 |
Why?
|
Hematologic Diseases | 1 | 1986 | 496 | 0.000 |
Why?
|
Lipids | 1 | 1992 | 3341 | 0.000 |
Why?
|
Microscopy, Electron | 1 | 1983 | 2561 | 0.000 |
Why?
|
Muscles | 1 | 1983 | 1576 | 0.000 |
Why?
|
Cytoskeleton | 1 | 1983 | 1170 | 0.000 |
Why?
|
Rabbits | 1 | 1983 | 4772 | 0.000 |
Why?
|